My retirem_老虎社区_美港股上老虎

2021-11-02

My retirement stock for the future 🚀

2 Best Biotech Stocks to Buy in November<blockquote>11月最值得买入的2只生物科技股</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":841072224,"tweetId":"841072224","gmtCreate":1635865742259,"gmtModify":1635866541326,"author":{"id":3567060979533928,"idStr":"3567060979533928","authorId":3567060979533928,"authorIdStr":"3567060979533928","name":"Reminiscent","avatar":"https://static.tigerbbs.com/756f10ded1f79212c0f44c111c0d9278","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>My retirement stock for the future 🚀&nbsp;</body></html>","htmlText":"<html><head></head><body>My retirement stock for the future 🚀&nbsp;</body></html>","text":"My retirement stock for the future 🚀","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/841072224","repostId":1135028228,"repostType":2,"repost":{"id":"1135028228","kind":"news","pubTimestamp":1635822901,"share":"https://www.laohu8.com/m/news/1135028228?lang=zh_CN&edition=full","pubTime":"2021-11-02 11:15","market":"us","language":"en","title":"2 Best Biotech Stocks to Buy in November<blockquote>11月最值得买入的2只生物科技股</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1135028228","media":"Motley Fool","summary":"Biotech stocks appear to be poised for a strong showing in November for a host of reasons. First and","content":"Biotech stocks appear to be poised for a strong showing in November for a host of reasons. First and foremost, the industry's biggest headwind this year -- drug pricing reform -- was conspicuously left out of the social spending bill recently released by the White House. Second, the latest earnings reports from top big pharma companies like&nbsp;Merck&nbsp;have been&nbsp;better than expectedso far. Lastly, scores of drugmakers are slated to release key clinical and regulatory updates this month.<blockquote>出于多种原因，生物科技股似乎有望在11月份表现强劲。首先，该行业今年最大的阻力——药品定价改革——明显被排除在白宫最近发布的社会支出法案之外。其次，顶级大型制药公司的最新收益报告，例如默克到目前为止，情况好于预期。最后，数十家制药商定于本月发布关键的临床和监管更新。</blockquote> Which&nbsp;biotech stocks&nbsp;could be the belles of the ball in November?Bionano Genomics(NASDAQ:BNGO)and&nbsp;Ocugen(NASDAQ:OCGN)are two names that growth-oriented investors should definitely have on the radars this month. Here's why.<blockquote>哪些生物科技股可能成为11月份的焦点？生物纳米基因组学（纳斯达克：BNGO）及奥库根（纳斯达克：OCGN）是成长型投资者本月绝对应该关注的两个名字。原因如下。</blockquote> Bionano Genomics: Time to buy this fallen angel<blockquote>Bionano Genomics：是时候购买这个堕落天使了</blockquote> Personalized medicine is the holy grail of biotech research. Despite numerous breakthroughs in the treatment of cancer with the advent of immunotherapy, a clinical success in this field is generally characterized by response rates as low as 30%. Researchers believe that these exceedingly low response rates stem from differences in the mutation type at both the nucleic acid and whole chromosomal level within a particular patient population. Cancer, in effect, is not a monolithic disease, making it impossible to develop a one-size-fits-all type of therapy.<blockquote>个性化医疗是生物技术研究的圣杯。尽管随着免疫疗法的出现在癌症治疗中取得了许多突破，但该领域的临床成功通常以低至30%的应答率为特征。研究人员认为，这些极低的应答率源于特定患者群体内核酸和全染色体水平突变类型的差异。实际上，癌症不是一种单一的疾病，因此不可能开发出一种放之四海而皆准的疗法。</blockquote> To boost the efficacy of these novel anti-cancer treatments, researchers thus require an accurate picture of the malignancy's genetic architecture at the individual level. That's where a company like Bionano Genomics comes into play. Bionano Genomicssportsa non-sequencing-based optical mapping technology known as the Saphyr System. The Saphyr System is designed to rapidly characterize extremely long strands of genomic DNA.<blockquote>因此，为了提高这些新型抗癌治疗的疗效，研究人员需要在个体水平上准确了解恶性肿瘤的遗传结构。这就是像Bionano Genomics这样的公司发挥作用的地方。Bionano GenomicsSport一种基于非测序的光学作图技术，称为Saphyr系统。Saphyr系统旨在快速表征极长的基因组DNA链。</blockquote> What's more, the biotech recently acquired the leading genomics data analysis software company BioDiscovery. This landmark acquisition could turn out to be a game-changing business development move for the company and its shareholders. In brief, BioDiscovery's NXClinical software solution for variant analysis, combined with the Saphyr System, has the potential to accelerate the adoption of optical genome mapping at large. Moreover, this potentially best-in-class platform might ultimately grab an outsize portion of this multi-billion dollar market within the next few years.<blockquote>此外，该生物技术公司最近收购了领先的基因组学数据分析软件公司BioDiscovery。对于公司及其股东来说，这一具有里程碑意义的收购可能会成为改变游戏规则的业务发展举措。简而言之，BioDiscovery用于变异分析的NXClinical软件解决方案与Saphyr系统相结合，有可能加速光学基因组图谱的广泛采用。此外，这个潜在的同类最佳平台最终可能会在未来几年内占据这个数十亿美元市场的很大一部分。</blockquote> Why should investors buy this stock in November? Bionano is slated to report third-quarter earnings on Nov. 4. While the biotech's Q3 revenue figure is unlikely to turn heads, investors should learn more about the long-term implications of this key acquisition. As a result, Bionano's beaten-down stock might finally start to show some signs of life after an eight-month downturn. Underscoring this point, the biotech's shares are currently down by a whopping 67% relative to their 52-week highs. Aggressive investors, in turn, may want to pick up some shares ahead of this upcoming earnings report.<blockquote>投资者为什么要在11月份购买这只股票？Bionano定于11月4日公布第三季度收益。虽然该生物技术公司第三季度的收入数据不太可能引人注目，但投资者应该更多地了解这一关键收购的长期影响。因此，Bionano遭受重创的股票在经历了八个月的低迷之后可能终于开始显示出一些复苏的迹象。该生物技术公司的股价目前较52周高点下跌了67%，这凸显了这一点。反过来，激进的投资者可能希望在即将发布的收益报告之前买入一些股票。</blockquote> Ocugen: An underappreciated COVID-19 vaccine stock<blockquote>Ocugen：被低估的COVID-19疫苗股票</blockquote> Thanks to its popularity onsocial media, Ocugen's shares have jumped by an astounding 547% so far this year. The biotech's appeal to the social media crowd isn't without reason, however. Ocugen's North American co-commercialization agreement with India's Bharat Biotech for the COVID-19 vaccine Covaxin is expected to lead to a monstrous rise in its top line in 2022 and beyond. Wall Street, in fact, thinks the vaccine's North American sales may top $400 million within the next two years.<blockquote>由于其在社交媒体上的受欢迎程度，Ocugen的股价今年迄今为止已上涨了547%，令人震惊。然而，该生物技术对社交媒体人群的吸引力并非没有道理。Ocugen与印度Bharat Biotech就COVID-19疫苗科瓦克辛达成的北美联合商业化协议预计将导致其营收在2022年及以后大幅增长。事实上，华尔街认为该疫苗在未来两年内在北美的销售额可能会超过4亿美元。</blockquote> While this experimental vaccine still has to undergo clinical testing in the U.S., as well as a regulatory review in Canada, before Ocugen can start earning revenue from it, the vaccine does appear to workfairly wellbased on its clinical trial data in India. As such, there is a solid basis to believe that this vaccine will eventually be approved in the U.S. and Canada.<blockquote>虽然这种实验性疫苗仍需在美国进行临床测试，并在加拿大进行监管审查，然后Ocugen才能开始从中获得收入，但根据其在印度的临床试验数据，该疫苗似乎确实效果相当好。因此，有充分的理由相信这种疫苗最终将在美国和加拿大获得批准。</blockquote> Why is Ocugen's stock a strong buy this month? Ocugen and its partner Bharat Biotech are expecting to receive word on the vaccine's emergency use listing (EUL) application from the World Health Organization (WHO) soon. The WHO has repeatedly asked Bharat Biotech for additional data prior to approving an EUL for Covaxin, leading to a lengthy delay for this key regulatory nod. But a green light could come as soon as Nov. 3, when the WHO's technical advisory group overseeing vaccine EULs meets again.<blockquote>为什么Ocugen的股票本月值得大力买入？Ocugen及其合作伙伴Bharat Biotech预计将很快收到世界卫生组织（世卫组织）关于该疫苗紧急使用清单（EUL）申请的消息。世卫组织在批准科瓦克辛EUL之前多次要求Bharat Biotech提供额外数据，导致这一关键监管机构的批准被长期拖延。但最早可能会在11月3日，届时世卫组织负责监督EUL疫苗的技术咨询小组将再次召开会议。</blockquote> Although Ocugen will not financially benefit from a WHO EUL due to the nature of its co-commercialization agreement with Bharat Biotech, it would be huge step in the right direction for the experimental vaccine. The biotech's stock, in turn, will likely continue to march higher in response to a positive EUL decision this month.<blockquote>尽管由于与Bharat Biotech的联合商业化协议的性质，Ocugen不会从WHO EUL中获得经济利益，但对于实验性疫苗来说，这将是朝着正确方向迈出的一大步。反过来，由于本月EUL的积极决定，该生物技术公司的股价可能会继续走高。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Best Biotech Stocks to Buy in November<blockquote>11月最值得买入的2只生物科技股</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Best Biotech Stocks to Buy in November<blockquote>11月最值得买入的2只生物科技股</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-11-02 11:15\n\n</h4>\n</header>\n<article>\nBiotech stocks appear to be poised for a strong showing in November for a host of reasons. First and foremost, the industry's biggest headwind this year -- drug pricing reform -- was conspicuously left out of the social spending bill recently released by the White House. Second, the latest earnings reports from top big pharma companies like&nbsp;Merck&nbsp;have been&nbsp;better than expectedso far. Lastly, scores of drugmakers are slated to release key clinical and regulatory updates this month.<blockquote>出于多种原因，生物科技股似乎有望在11月份表现强劲。首先，该行业今年最大的阻力——药品定价改革——明显被排除在白宫最近发布的社会支出法案之外。其次，顶级大型制药公司的最新收益报告，例如默克到目前为止，情况好于预期。最后，数十家制药商定于本月发布关键的临床和监管更新。</blockquote> Which&nbsp;biotech stocks&nbsp;could be the belles of the ball in November?Bionano Genomics(NASDAQ:BNGO)and&nbsp;Ocugen(NASDAQ:OCGN)are two names that growth-oriented investors should definitely have on the radars this month. Here's why.<blockquote>哪些生物科技股可能成为11月份的焦点？生物纳米基因组学（纳斯达克：BNGO）及奥库根（纳斯达克：OCGN）是成长型投资者本月绝对应该关注的两个名字。原因如下。</blockquote> Bionano Genomics: Time to buy this fallen angel<blockquote>Bionano Genomics：是时候购买这个堕落天使了</blockquote> Personalized medicine is the holy grail of biotech research. Despite numerous breakthroughs in the treatment of cancer with the advent of immunotherapy, a clinical success in this field is generally characterized by response rates as low as 30%. Researchers believe that these exceedingly low response rates stem from differences in the mutation type at both the nucleic acid and whole chromosomal level within a particular patient population. Cancer, in effect, is not a monolithic disease, making it impossible to develop a one-size-fits-all type of therapy.<blockquote>个性化医疗是生物技术研究的圣杯。尽管随着免疫疗法的出现在癌症治疗中取得了许多突破，但该领域的临床成功通常以低至30%的应答率为特征。研究人员认为，这些极低的应答率源于特定患者群体内核酸和全染色体水平突变类型的差异。实际上，癌症不是一种单一的疾病，因此不可能开发出一种放之四海而皆准的疗法。</blockquote> To boost the efficacy of these novel anti-cancer treatments, researchers thus require an accurate picture of the malignancy's genetic architecture at the individual level. That's where a company like Bionano Genomics comes into play. Bionano Genomicssportsa non-sequencing-based optical mapping technology known as the Saphyr System. The Saphyr System is designed to rapidly characterize extremely long strands of genomic DNA.<blockquote>因此，为了提高这些新型抗癌治疗的疗效，研究人员需要在个体水平上准确了解恶性肿瘤的遗传结构。这就是像Bionano Genomics这样的公司发挥作用的地方。Bionano GenomicsSport一种基于非测序的光学作图技术，称为Saphyr系统。Saphyr系统旨在快速表征极长的基因组DNA链。</blockquote> What's more, the biotech recently acquired the leading genomics data analysis software company BioDiscovery. This landmark acquisition could turn out to be a game-changing business development move for the company and its shareholders. In brief, BioDiscovery's NXClinical software solution for variant analysis, combined with the Saphyr System, has the potential to accelerate the adoption of optical genome mapping at large. Moreover, this potentially best-in-class platform might ultimately grab an outsize portion of this multi-billion dollar market within the next few years.<blockquote>此外，该生物技术公司最近收购了领先的基因组学数据分析软件公司BioDiscovery。对于公司及其股东来说，这一具有里程碑意义的收购可能会成为改变游戏规则的业务发展举措。简而言之，BioDiscovery用于变异分析的NXClinical软件解决方案与Saphyr系统相结合，有可能加速光学基因组图谱的广泛采用。此外，这个潜在的同类最佳平台最终可能会在未来几年内占据这个数十亿美元市场的很大一部分。</blockquote> Why should investors buy this stock in November? Bionano is slated to report third-quarter earnings on Nov. 4. While the biotech's Q3 revenue figure is unlikely to turn heads, investors should learn more about the long-term implications of this key acquisition. As a result, Bionano's beaten-down stock might finally start to show some signs of life after an eight-month downturn. Underscoring this point, the biotech's shares are currently down by a whopping 67% relative to their 52-week highs. Aggressive investors, in turn, may want to pick up some shares ahead of this upcoming earnings report.<blockquote>投资者为什么要在11月份购买这只股票？Bionano定于11月4日公布第三季度收益。虽然该生物技术公司第三季度的收入数据不太可能引人注目，但投资者应该更多地了解这一关键收购的长期影响。因此，Bionano遭受重创的股票在经历了八个月的低迷之后可能终于开始显示出一些复苏的迹象。该生物技术公司的股价目前较52周高点下跌了67%，这凸显了这一点。反过来，激进的投资者可能希望在即将发布的收益报告之前买入一些股票。</blockquote> Ocugen: An underappreciated COVID-19 vaccine stock<blockquote>Ocugen：被低估的COVID-19疫苗股票</blockquote> Thanks to its popularity onsocial media, Ocugen's shares have jumped by an astounding 547% so far this year. The biotech's appeal to the social media crowd isn't without reason, however. Ocugen's North American co-commercialization agreement with India's Bharat Biotech for the COVID-19 vaccine Covaxin is expected to lead to a monstrous rise in its top line in 2022 and beyond. Wall Street, in fact, thinks the vaccine's North American sales may top $400 million within the next two years.<blockquote>由于其在社交媒体上的受欢迎程度，Ocugen的股价今年迄今为止已上涨了547%，令人震惊。然而，该生物技术对社交媒体人群的吸引力并非没有道理。Ocugen与印度Bharat Biotech就COVID-19疫苗科瓦克辛达成的北美联合商业化协议预计将导致其营收在2022年及以后大幅增长。事实上，华尔街认为该疫苗在未来两年内在北美的销售额可能会超过4亿美元。</blockquote> While this experimental vaccine still has to undergo clinical testing in the U.S., as well as a regulatory review in Canada, before Ocugen can start earning revenue from it, the vaccine does appear to workfairly wellbased on its clinical trial data in India. As such, there is a solid basis to believe that this vaccine will eventually be approved in the U.S. and Canada.<blockquote>虽然这种实验性疫苗仍需在美国进行临床测试，并在加拿大进行监管审查，然后Ocugen才能开始从中获得收入，但根据其在印度的临床试验数据，该疫苗似乎确实效果相当好。因此，有充分的理由相信这种疫苗最终将在美国和加拿大获得批准。</blockquote> Why is Ocugen's stock a strong buy this month? Ocugen and its partner Bharat Biotech are expecting to receive word on the vaccine's emergency use listing (EUL) application from the World Health Organization (WHO) soon. The WHO has repeatedly asked Bharat Biotech for additional data prior to approving an EUL for Covaxin, leading to a lengthy delay for this key regulatory nod. But a green light could come as soon as Nov. 3, when the WHO's technical advisory group overseeing vaccine EULs meets again.<blockquote>为什么Ocugen的股票本月值得大力买入？Ocugen及其合作伙伴Bharat Biotech预计将很快收到世界卫生组织（世卫组织）关于该疫苗紧急使用清单（EUL）申请的消息。世卫组织在批准科瓦克辛EUL之前多次要求Bharat Biotech提供额外数据，导致这一关键监管机构的批准被长期拖延。但最早可能会在11月3日，届时世卫组织负责监督EUL疫苗的技术咨询小组将再次召开会议。</blockquote> Although Ocugen will not financially benefit from a WHO EUL due to the nature of its co-commercialization agreement with Bharat Biotech, it would be huge step in the right direction for the experimental vaccine. The biotech's stock, in turn, will likely continue to march higher in response to a positive EUL decision this month.<blockquote>尽管由于与Bharat Biotech的联合商业化协议的性质，Ocugen不会从WHO EUL中获得经济利益，但对于实验性疫苗来说，这将是朝着正确方向迈出的一大步。反过来，由于本月EUL的积极决定，该生物技术公司的股价可能会继续走高。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/11/01/2-best-biotech-stocks-to-buy-in-november/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/11/01/2-best-biotech-stocks-to-buy-in-november/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135028228","content_text":"Biotech stocks appear to be poised for a strong showing in November for a host of reasons. First and foremost, the industry's biggest headwind this year -- drug pricing reform -- was conspicuously left out of the social spending bill recently released by the White House. Second, the latest earnings reports from top big pharma companies like Merck have been better than expectedso far. Lastly, scores of drugmakers are slated to release key clinical and regulatory updates this month.\nWhich biotech stocks could be the belles of the ball in November?Bionano Genomics(NASDAQ:BNGO)and Ocugen(NASDAQ:OCGN)are two names that growth-oriented investors should definitely have on the radars this month. Here's why.\nBionano Genomics: Time to buy this fallen angel\nPersonalized medicine is the holy grail of biotech research. Despite numerous breakthroughs in the treatment of cancer with the advent of immunotherapy, a clinical success in this field is generally characterized by response rates as low as 30%. Researchers believe that these exceedingly low response rates stem from differences in the mutation type at both the nucleic acid and whole chromosomal level within a particular patient population. Cancer, in effect, is not a monolithic disease, making it impossible to develop a one-size-fits-all type of therapy.\nTo boost the efficacy of these novel anti-cancer treatments, researchers thus require an accurate picture of the malignancy's genetic architecture at the individual level. That's where a company like Bionano Genomics comes into play. Bionano Genomicssportsa non-sequencing-based optical mapping technology known as the Saphyr System. The Saphyr System is designed to rapidly characterize extremely long strands of genomic DNA.\nWhat's more, the biotech recently acquired the leading genomics data analysis software company BioDiscovery. This landmark acquisition could turn out to be a game-changing business development move for the company and its shareholders. In brief, BioDiscovery's NXClinical software solution for variant analysis, combined with the Saphyr System, has the potential to accelerate the adoption of optical genome mapping at large. Moreover, this potentially best-in-class platform might ultimately grab an outsize portion of this multi-billion dollar market within the next few years.\nWhy should investors buy this stock in November? Bionano is slated to report third-quarter earnings on Nov. 4. While the biotech's Q3 revenue figure is unlikely to turn heads, investors should learn more about the long-term implications of this key acquisition. As a result, Bionano's beaten-down stock might finally start to show some signs of life after an eight-month downturn. Underscoring this point, the biotech's shares are currently down by a whopping 67% relative to their 52-week highs. Aggressive investors, in turn, may want to pick up some shares ahead of this upcoming earnings report.\nOcugen: An underappreciated COVID-19 vaccine stock\nThanks to its popularity onsocial media, Ocugen's shares have jumped by an astounding 547% so far this year. The biotech's appeal to the social media crowd isn't without reason, however. Ocugen's North American co-commercialization agreement with India's Bharat Biotech for the COVID-19 vaccine Covaxin is expected to lead to a monstrous rise in its top line in 2022 and beyond. Wall Street, in fact, thinks the vaccine's North American sales may top $400 million within the next two years.\nWhile this experimental vaccine still has to undergo clinical testing in the U.S., as well as a regulatory review in Canada, before Ocugen can start earning revenue from it, the vaccine does appear to workfairly wellbased on its clinical trial data in India. As such, there is a solid basis to believe that this vaccine will eventually be approved in the U.S. and Canada.\nWhy is Ocugen's stock a strong buy this month? Ocugen and its partner Bharat Biotech are expecting to receive word on the vaccine's emergency use listing (EUL) application from the World Health Organization (WHO) soon. The WHO has repeatedly asked Bharat Biotech for additional data prior to approving an EUL for Covaxin, leading to a lengthy delay for this key regulatory nod. But a green light could come as soon as Nov. 3, when the WHO's technical advisory group overseeing vaccine EULs meets again.\nAlthough Ocugen will not financially benefit from a WHO EUL due to the nature of its co-commercialization agreement with Bharat Biotech, it would be huge step in the right direction for the experimental vaccine. The biotech's stock, in turn, will likely continue to march higher in response to a positive EUL decision this month.","news_type":1,"symbols_score_info":{"OCGN":0.9,"BNGO":0.9}},"isVote":1,"tweetType":1,"viewCount":1818,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":31,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/841072224"}